Researchers found that the local release of dopamine – a molecule best known for its role in the brain’s reward system – is a key factor in acquiring new motor skills.

More and more research indicates that GLP-1 analogues can have a blunting effect on addictions like drugs and alcohol. Drug ...

DelveInsight's Parkinson's Disease Pipeline report depicts a robust space with 130+ active players working to develop 150+ ...

The average American spends 4 hours and 34 minutes daily on their phone. When we’re not glued to our phones, we’re fixated on ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to ...

Phone addiction rewires brain chemistry by lowering baseline dopamine levels, making normal activities feel boring and ...

Diabetes Care Bromocriptine: A Sympatholytic, D2-dopamine Agonist for the Treatment of Type 2 Diabetes Ralph A. DeFronzo, MD Disclosures Diabetes Care. 2011;34 (4):789-794.

Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

In 2004, van Camp et al 1 published the first large observational study describing cardiac valve dysfunction in patients receiving the dopamine agonist (DA) pergolide for Parkinson’s disease.

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates ...